Cellectar Biosciences (CLRB) vs IN8bio (INAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IN8bio (INAB) has outperformed Cellectar Biosciences (CLRB) over the past year, losing 42.7% versus a loss of 70.7%. Over five years, INAB leads with a -99.2% price change compared with -99.5% for CLRB. IN8bio is the larger company by market cap ($13.6 million vs $13.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | INAB |
|---|---|---|
| Share price | $1.40 | $1.38 |
| Market cap | $13.23M | $13.60M |
| 1-day change | -7.28% | -1.43% |
| YTD return | -52.54% | -41.03% |
| 1-year return | -70.71% | -42.74% |
| 5-year return | -99.49% | -99.23% |
| EPS (TTM) | $-3.46 | $-1.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $2.73 |
| 52-week low | $1.34 | $0.88 |
| Distance from 52-week high | -72.39% | -49.45% |
| Analyst consensus | none | none |
| Avg. price target upside | +721.43% | +407.25% |
| Average volume | 63.86K | 58.36K |
| Shares outstanding | 9.45M | 9.86M |
| Employees | 11 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed CLRB by 28.0 percentage points over the past year.
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Healthcare · Biotechnology · 11 employees
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Healthcare · Biotechnology · 18 employees
CLRB vs INAB FAQ
Which is bigger, Cellectar Biosciences or IN8bio?
IN8bio (INAB) is larger, with a market capitalization of $13.60M compared with $13.23M for Cellectar Biosciences (CLRB).
Which stock has performed better over the past year, CLRB or INAB?
INAB returned -42.74% over the past 12 months, compared with -70.71% for CLRB (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and IN8bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.